Asia · Mercados regionales · The Investor

Samsung Bioepis secures 10-year biosimilar supply deal in Brazil

Publicado por The Investor · Corea del Sur hace 21 h

Samsung Bioepis said Tuesday it has secured a 10-year deal to exclusively supply its rare disease biosimilar SB12 to Brazil's public health system, strengthenin ...

Leer el artículo completo en The Investor Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.theinvestor.co.kr)

Samsung Bioepis secures 10-year biosimilar supply deal in Brazil

También te puede interesar

ดอลลาร์อ่อนค่า สอดคล้องบอนด์ยีลด์อ่อนตัว

Big-ticket IPOs have struggled to deliver bumper listing gains. Can Mukesh Ambani backed Reliance Jio buck the trend?

US markets set to open lower as AI stocks slide and oil tops $100

Monetary policy could turn accommodative as AI productivity gains take hold: MAS chief economist

Faster delivery, easier credit fuel South-east Asia e-commerce: survey

Artha Bharat to shift two GIFT City funds to Abu Dhabi over tax hurdles

Samsung Bioepis secures 10-year biosimilar supply deal in Brazil

Compartir

También te puede interesar

ดอลลาร์อ่อนค่า สอดคล้องบอนด์ยีลด์อ่อนตัว

Big-ticket IPOs have struggled to deliver bumper listing gains. Can Mukesh Ambani backed Reliance Jio buck the trend?

US markets set to open lower as AI stocks slide and oil tops $100

Monetary policy could turn accommodative as AI productivity gains take hold: MAS chief economist

Faster delivery, easier credit fuel South-east Asia e-commerce: survey

Artha Bharat to shift two GIFT City funds to Abu Dhabi over tax hurdles